請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67808
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳世雄 | |
dc.contributor.author | Wen-Jie Shen | en |
dc.contributor.author | 沈文傑 | zh_TW |
dc.date.accessioned | 2021-06-17T01:51:06Z | - |
dc.date.available | 2022-08-01 | |
dc.date.copyright | 2017-08-01 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-07-24 | |
dc.identifier.citation | 1. McBride, M. J. Shining a light on an opportunistic pathogen. J. Bacteriol. 192, 6325–6326 (2010).
2. Henrichsen J. The occurrence of twitching motility among gram-negative bacteria. Acta Pathol Microbiol Scand B 83, 171–178 (1975). 3. Henriksen, S. D. Moraxella, Acinetobacter, and the Mimeae. Bacteriol. Rev. 37, 522–561 (1973). 4. Baumann, P. Isolation of Acinetobacter from soil and water. J. Bacteriol. 96, 39–42 (1968). 5. Baumann P, Doudoroff M, S. R. A Study of the Moraxellk Group II. Oxidative-negative Species (Genus Acinetobacter). J. Bacteriol. 95, 1520–1541 (1968). 6. Bergogne-Bérézin E, T. K. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. 9, 148–165 (1996). 7. Nemec, A. Classification and nomenclature of species in the genus Acinetobacter. 15–16 (2017). 8. Liu, Z. et al. Biodegradation of Phenol by Bacteria Strain Acinetobacter Calcoaceticus PA Isolated from Phenolic Wastewater. Int. J. Environ. Res. Public Heal. 13, (2016). 9. Abdel-el-haleem, D. Acinetobacter : environmental and biotechnological applications. African J. Biotechnol. Vol. 2, 71–74 (2003). 10. Seifert, H., Baginski, R., Schulze, A. & Pulverer, G. The Distribution of Acinetobacter Species in Clinical Culture Materials. Zentralblatt für Bakteriol. 279, 544–552 (1993). 11. Bouvet, P. J. M. & Grimont, P. a. D. Taxonomy of the Genus Acinetobacter with the Recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and Emended Descriptions of Acinetobacter calcoaceticus a. Int. J. Syst. Bacteriol. 36, 228–240 (1986). 12. Espinal, P., Seifert, H., Dijkshoorn, L., Vila, J. & Roca, I. Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin. Microbiol. Infect. 18, 1097–1103 (2012). 13. Johnson, J. K. et al. Comparison of molecular typing methods for the analyses of Acinetobacter baumannii from ICU patients. Diagn. Microbiol. Infect. Dis. 86, 345–350 (2016). 14. Gräser, Y. et al. Epidemiological study of an Acinetobacter baumannii outbreak by using polymerase chain reaction fingerprinting. J. Clin. Microbiol. 31, 2417–2420 (1993). 15. Zhang, H.-Z., Zhang, J.-S. & Qiao, L. The Acinetobacter baumannii group: a systemic review. World J. Emerg. Med. 4, 169–74 (2013). 16. Dijkshoorn, L., Nemec, A. & Seifert, H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5, 939–951 (2007). 17. Wendt, C., Dietze, B., Dietz, E. & Ruden, H. Survival of Acinetobacter baumannii on dry surfaces. J. Clin. Microbiol. 35, 1394–1397 (1997). 18. Jawad, A., Seifert, H., Snelling, A. M. & Heritage, J. Survival of Acinetobacter baumannii on Dry Surfaces : Comparison of Outbreak and Sporadic Isolates. J. Clin. Microbiol. 36, 1938–1941 (1998). 19. Tomaras, A. P., Dorsey, C. W., Edelmann, R. E. & Actis, L. A. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: Involvement of a novel chaperone-usher pili assembly system. Microbiology 149, 3473–3484 (2003). 20. Morgan, D. J. et al. Frequent Multidrug-Resistant Acinetobacter baumannii Contamination of Gloves , Gowns , and Hands of Healthcare Workers. Infect. Control Hosp. Epidemiol. 31, 716–721 (2010). 21. Cefai, C., Gould, F. K. & Ne, T. An outbreak of Acinetobacter respiratory tract infection resulting from incomplete disinfection of ventilatory equipment. J. Hosp. Infect. 15, 177–182 (1990). 22. Allen, D., Green, T., Hospital, W., Lane, R. & Liverpool, L. Hospital outbreak of multi-resistant anitratus : an airborne mode Acinetobacter of spread ? J. Hosp. Infect. 9, 110–119 (1987). 23. Sherertz, R. J. & Sullivan, M. L. An Outbreak of Infections with Acinetobacter calcoaceticus in Burn Patients : Contamination of Patients ’ Mattresses. J. Infect. Dis. 151, 252–258 (1985). 24. Liou, M., Lin, M., Chang, K. & Kuo, H. Carbapenem-resistant Acinetobacter baumannii in Taiwan. 22, 81–87 (2010). 25. Su, C. et al. Increase of Carbapenem-Resistant Acinetobacter baumannii Infection in Acute Care Hospitals in Taiwan : Association with Hospital Antimicrobial Usage. PLoS One 7, e37788 (2012). 26. Zowawi, H. M. et al. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolates in the Gulf Cooperation Council States : Dominance of OXA-23-Type Producers. 53, 896–903 (2015). 27. Ling, B. & Jia, X. Characterization of carbapenem- resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. 6, 1–9 (2015). 28. Hospital, S. et al. Acinetobacter baumannii Nosocomial Pneumonia in Tertiary Care Hospitals in Thailand. 95, 23–33 (2012). 29. Qi, J. et al. Carbapenem Resistance in Gram-Negative Bacteria : The Not-So-Little Problem in the Little Red Dot. Microorganisms 4, 13 (2016). 30. Farrell, D. J., Sader, H. S., Flamm, R. K. & Jones, R. N. International Journal of Antimicrobial Agents Ceftolozane / tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres ( 2012 ). Int. J. Antimicrob. Agents 43, 533–539 (2014). 31. Olaitan, A. O. et al. International Journal of Infectious Diseases. Int. J. Infect. Dis. 17, e469–e470 (2013). 32. Almasaudi, S. B. Acinetobacter spp . as nosocomial pathogens : Epidemiology and resistance features. SAUDI J. Biol. Sci. (2016). 33. Ortiz-leyba, C., Jime, F., Barrero-almodo, A. E. & Gili-miner, M. Risk Factors for Acinetobacter baumannii Nosocomial Bacteremia in Critically Ill Patients : A Cohort Study. Clin. Infect. Dis. 33, 939–946 (2001). 34. Fukuta, Y. et al. American Journal of Infection Control Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am. J. Infect. Control 41, 1249–1252 (2013). 35. Chopra, T. et al. Risk Factors and Outcomes for Patients with Bloodstream Infection Due to Acinetobacter baumannii-calcoaceticus Complex. Antimicrob. Agents Chemother. 58, 4630–4635 (2014). 36. Falagas, M. E., Karveli, E. A., Kelesidis, I. & Kelesidis, T. Community-acquired Acinetobacter infections. Eur. J. Clin. Microbiol. Infect. Dis. 26, 857–868 (2007). 37. Chusri, S., Chongsuvivatwong, V., Rivera, J. I., Silpapojakul, K. & Singkhamanan, K. Clinical Outcomes of Hospital-Acquired Infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob. Agents Chemother. 58, 4172–4179 (2014). 38. Peleg, A. Y. et al. Galleria mellonella as a Model System To Study Acinetobacter baumannii Pathogenesis and Therapeutics. Antimicrob. Agents Chemother. 53, 2605–2609 (2009). 39. Vallejo, J. A., Beceiro, A., Rumbo-feal, S., Rodríguez-palero, M. J. & Russo, T. A. Optimisation of the Caenorhabditis elegans model for studying the pathogenesis of opportunistic Acinetobacter baumannii. Int. J. Antimicrob. Agents (2015). 40. Wolff, M., Pocidalo, J., Walker, F. & Carbon, C. Use of a New Mouse Model of Acinetobacter baumannii Pneumonia To Evaluate the Postantibiotic Effect of Imipenem. Antimicrob. Agents Chemother. 41, 345–351 (1997). 41. Luo, G. et al. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother 67, 1439–1445 (2012). 42. Biswas, I. Genetic tools for manipulating Acinetobacter baumannii genome: An overview. J. Med. Microbiol. 64, 657–669 (2015). 43. Bonten, M. J. M., Weinstein, R. A., Bonten, M. J. M. & Weinstein, R. A. The Role of Colonization in the Pathogenesis of Nosocomial Infections. Infect. Control Hosp. Epidemiol. 17, 193–200 (2017). 44. Vijayakumar, S. et al. Biofilm Formation and Motility Depend on the Nature of the Acinetobacter baumannii Clinical Isolates. Front. Public Heal. 4, 105 (2016). 45. Vila, J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 80, 56–60 (2012). 46. Brossard, K. A. & Campagnari, A. A. The Acinetobacter baumannii Biofilm-Associated Protein Plays a Role in Adherence to Human Epithelial Cells. Infect. Immun. 80, 228–233 (2012). 47. Erridge, C., Moncayo-nieto, O. L., Morgan, R., Young, M. & Poxton, I. R. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. 56, 165–171 (2007). 48. Cress, B. F. et al. Masquerading microbial pathogens: Capsular polysaccharides mimic host-tissue molecules. FEMS Microbiol. Rev. 38, 660–697 (2014). 49. Tankovic, J. et al. Hospital Outbreak of Imipenem-Resistant Acinetobacter baumannii by Phenotypic and Genotypic Typing Methods. J. Clin. Invest. 32, 2677–2681 (1994). 50. Recommendations, T. & Inpatients, F. A. Antibiotic Guidelines 2015-2016. (2016). 51. Wilharm, G., Piesker, J. & Laue, M. DNA Uptake by the Nosocomial Pathogen Acinetobacter baumannii. J. Bacteriol. 195, 4146–4153 (2013). 52. Maragakis, L. L. & Perl, T. M. Acinetobacter baumannii : Epidemiology , Antimicrobial Resistance , and Treatment Options. Clin. Infect. Dis. 46, 1254–1263 (2008). 53. Poirel, L. & Nordmann, P. Carbapenem resistance in Acinetobacter baumannii : mechanisms and epidemiology. Eur. Soc. Clin. Infect. Dis. 12, 826–836 (2006). 54. López-Hernández S, Alarcón T, L.-B. M. Carbapenem Resistance Mediated by Beta-Lactamases in Clinical Isolates of Acinetobacter baumannii in Spain. Eur J Clin Microbiol Infect Dis 17, 282–285 (1998). 55. Lu, P. L., Doumith, M., Livermore, D. M., Chen, T. P. & Woodford, N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: Spread of plasmid-borne OXA-72 carbapenemase. J. Antimicrob. Chemother. 63, 641–647 (2009). 56. Turton, J. F. et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258, 72–77 (2006). 57. Rumbo, C. et al. Horizontal Transfer of the OXA-24 Carbapenemase Gene via Outer Membrane Vesicles : a New Mechanism of Dissemination of Carbapenem Resistance Genes in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55, 3084–3090 (2011). 58. Karageorgopoulos, D. E. & Falagas, M. E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8, 751–762 (2008). 59. Chen, Z. et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Nat. Publ. Gr. 1–8 (2015). 60. Russo, T. A. et al. The K1 Capsular Polysaccharide from Acinetobacter baumannii Is a Potential Therapeutic Target via Passive Immunization. Infect. Immun. 81, 915–922 (2013). 61. Robbins, J. B., Austrian, R. & Rastogi, S. C. Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive ’ Iypes Within Groups. J. Infect. Dis. 148, 1136–1159 (1983). 62. Ferna, V. et al. Polysaccharide Vaccine Against Haemophilus influenzae Type b. Science (80-. ). 305, 522–526 (2004). 63. Avci, F. Y., Li, X., Tsuji, M. & Kasper, D. L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat. Med. 17, 1602–1609 (2011). 64. Clifford M. Snapper, J. J. M. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J. Immunol. 157, 2229–2233 (1996). 65. Jones, C., Lane, B., Mimms, S. & Uk, H. E. N. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An. da Acad. Bras. Ciência 77, 293–324 (2005). 66. Nothaft, H. & Szymanski, C. M. Protein glycosylation in bacteria: sweeter than ever. Nat. Rev. Microbiol. 8, 765–778 (2010). 67. Tan, F. Y. Y., Tang, C. M. & Exley, R. M. Sugar coating : bacterial protein glycosylation and host – microbe interactions. Trends Biochem. Sci. 40, 342–350 (2015). 68. Dell, A., Galadari, A., Sastre, F. & Hitchen, P. Similarities and differences in the glycosylation mechanisms in prokaryotes and eukaryotes. Int. J. Microbiol. 2010, (2010). 69. Stepper, J. et al. Cysteine S -glycosylation , a new post-translational modification found in glycopeptide bacteriocins. FEBS Lett. 585, 645–650 (2011). 70. Valguarnera, E., Kinsella, R. L. & Feldman, M. F. Sugar and Spice Make Bacteria Not Nice : Protein Glycosylation and Its Influence in Pathogenesis. J. Mol. Biol. 428, 3206–3220 (2016). 71. Xu, C. & Ng, D. T. W. Glycosylation-directed quality control of protein folding. Nat. Publ. Gr. 16, 742–752 (2015). 72. Szymanski, C. M., Yao, R., Cheryl, P., Trust, T. J. & Guerry, P. Evidence for a system of general protein glycosylation in Campylobacter jejuni. Mol. Microbiol. 32, 1022–1030 (1999). 73. Gerber, S. et al. Mechanism of Bacterial Oligosaccharyltransferase. J. Biol. Chem. 288, 8849–8861 (2013). 74. Szymanski, C. M., Burr, D. H. & Guerry, P. Campylobacter Protein Glycosylation Affects Host Cell Interactions. Infect. Immun. 70, 2242–2244 (2002). 75. Asakura, H. et al. Helicobacter pylori HP0518 affects flagellin glycosylation to alter bacterial motility. Mol. Microbiol. 78, 1130–1144 (2010). 76. Goon, S., Kelly, J. F., Logan, S. M., Ewing, C. P. & Guerry, P. Pseudaminic acid , the major modification on Campylobacter flagellin , is synthesized via the Cj1293 gene. Mol. Microbiol. 50, 659–671 (2003). 77. Fletcher, C. M., Coyne, M. J., Villa, O. F., Chatzidaki-livanis, M. & Comstock, L. E. A General O-Glycosylation System Important to the Physiology of a Major Human Intestinal Symbiont. Cell 137, 321–331 (2009). 78. Lithgow, K. V et al. A general protein O-glycosylation system within the Burkholderia cepacia complex is involved in motility and virulence. Mol. Microbiol. 92, 116–137 (2014). 79. Vik, Å. et al. Broad spectrum O-linked protein glycosylation in the human pathogen Neisseria gonorrhoeae. Proc. Natl. Acad. Sci. U. S. A. 106, 4447–4452 (2009). 80. Egge-jacobsen, W. et al. O -Linked Glycosylation of the PilA Pilin Protein of Francisella tularensis : Identification of the Endogenous Protein-Targeting Oligosaccharyltransferase and Characterization of the Native Oligosaccharide. J. Bacteriol. 193, 5487–5497 (2011). 81. Gallagher, A., Aduse-opoku, J., Rangarajan, M., Slaney, J. M. & Curtis, M. A. Glycosylation of the Arg-gingipains of Porphyromonas gingivalis and Comparison with Glycoconjugate Structure and Synthesis in other Bacteria. Curr. Protein Pept. Sci. 427–441 (2003). 82. Iwashkiw, J. A. et al. Identification of a General O-linked Protein Glycosylation System in Acinetobacter baumannii and Its Role in Virulence and Biofilm Formation. PLoS Pathog. 8, (2012). 83. Lees-Miller, R. G. et al. A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii. Mol. Microbiol. 89, 816–830 (2013). 84. Yang, F. et al. A medically relevant capsular polysaccharide in Acinetobacter baumannii is a potential vaccine candidate. Vaccine 1–8 (2017). 85. Arbatsky, N. P. et al. Structure of the neutral capsular polysaccharide of Acinetobacter baumannii NIPH146 that carries the KL37 capsule gene cluster. Carbohydr. Res. 413, 12–15 (2015). 86. Koebnik, R., Locher, K. P. & Van, P. MicroReview Structure and function of bacterial outer membrane proteins : barrels in a nutshell. Mol. Microbiol. 37, 239–253 (2000). 87. Arora, A., Abildgaard, F., Bushweller, J. H. & Tamm, L. K. Structure of outer membrane protein A transmembrane domain by NMR spectroscopy. Nat. Struct. Biol. 8, (2001). 88. Hong, H., Szabo, G. & Tamm, L. K. Electrostatic couplings in OmpA ion-channel gating suggest a mechanism for pore opening. Nat. Chem. Biol. 2, 627–635 (2006). 89. Koebnik, R. Membrane Assembly of the Escherichia coli Outer Membrane Protein OmpA : Exploring Sequence Constraints on Transmembrane b -Strands. J. Mol. Biol. 285, 1801–1810 (1999). 90. Aykanat, T. & Ã, H. B. D. An outer membrane protein A ( ompA ) homologue from the photosynthetic purple sulfur bacterium Allochromatium vinosum. Microbiol. Res. 162, (2007). 91. Alphen, V. & Acta, B. B. The C-terminal sequence conservation betweenOmpA-related outer membrane proteins and MotBsuggests a common function in both Gram-positiveand Gram-negative bacteria, possibly in theinteraction of these domains with peptidogiycan. Mol. Microbiol. 12, 333–334 (1994). 92. Confer, A. W. & Ayalew, S. The OmpA family of proteins : Roles in bacterial pathogenesis and immunity. Vet. Microbiol. 163, 207–222 (2013). 93. Gaddy, J. A., Tomaras, A. P. & Actis, L. A. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect. Immun. 77, 3150–3160 (2009). 94. Park, J. S. et al. Mechanism of anchoring of OmpA protein to the cell wall peptidoglycan of the gram-negative bacterial outer membrane. FASEB J. 26, 219–228 (2012). 95. Moon, D. C. et al. Acinetobacter baumannii Outer Membrane Protein A Modulates the Biogenesis of Outer Membrane Vesicles §. J. Microbiol. 50, 155–160 (2012). 96. Jin, J. S. et al. Acinetobacter baumannii Secretes Cytotoxic Outer Membrane Protein A via Outer Membrane Vesicles. PLoS One 6, (2011). 97. Choi, C. H. et al. Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell. Microbiol. 7, 1127–1138 (2005). 98. Chalifour, A. et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production. Blood 104, 1778–1784 (2004). 99. Jeannin, P. et al. Outer membrane protein A ( OmpA ): a new pathogen-associated molecular pattern that interacts with antigen presenting cells — impact on vaccine strategies. Vaccine 20, 23–27 (2002). 100. Ahmad, T. A., Tawfik, D. M., Sheweita, S. A., Haroun, M. & El-Sayed, L. H. Development of immunization trials against Acinetobacter baumannii. Trials Vaccinol. 5, 53–60 (2016). 101. Luke, N. R. et al. Identification and characterization of a glycosyltransferase involved in acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect. Immun. 78, 2017–2023 (2010). 102. Burgess, J. A., Walter, N., Corthals, G. L., Hochstrasser, D. F. & Sanchez, J. Exploitation of specific properties of trifluoroethanol for extraction and separation. Proteomics 3, 1418–1424 (2003). 103. Chen, L.-K. et al. Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 13, 154 (2013). 104. Zamze, S. et al. Recognition of Bacterial Capsular Polysaccharides and Lipopolysaccharides by the Macrophage Mannose Receptor. J. Biol. Chem. 277, 41613–41623 (2002). 105. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, H. G. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell. Proteomics 1, 791–804 (2002). 106. Ma, J., Hart, G. W., Ma, J. & Hart, G. W. Analysis of Protein O-GlcNAcylation by Mass Spectrometry. Curr. Protoc. Protein Sci. 24.10.1-24.10.16 (2017). 107. Møller, H. J., Heinegård, D. & Poulsen, J. H. Combined alcian blue and silver staining of subnanogram quantities of proteoglycans and glycosaminoglycans in sodium dodecyl sulfate-polyacrylamide gels. Anal. Biochem. 209, 169–75 (1993). 108. Gail Lorenz Miller. Use of Dinitrosalicylic Acid Reagent for Determination of Reducing Sugar GAIL. Anal. Chem. 31, 426–428 (1959). 109. Helsens, K., Martens, L., Vandekerckhove, J. & Gevaert, K. MascotDatfile: An open-source library to fully parse and analyse MASCOT MS/MS search results. Proteomics 7, 364–366 (2007). 110. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–72 (2008). 111. Edgar, R. C., Drive, R. M. & Valley, M. MUSCLE : multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004). 112. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, 320–324 (2014). 113. Roy, A., Kucukural, A. & Zhang, Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738 (2010). 114. Pruitt, K. D., Tatusova, T. & Maglott, D. R. NCBI reference sequences (RefSeq): A curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 35, 61–65 (2007). 115. Seltmann, G. & Holst, O. The Bacterial Cell Wall. (2002). 116. Vosseller, K. et al. Quantitative analysis of both protein expression and serine/threonine post-translational modifications through stable isotope labeling with dithiothreitol. Proteomics 5, 388–398 (2005). 117. Merry, T. & Astrautsova, S. Chemical and Enzymatic Release of Glycans from Glycoproteins. Methods Mol. Biol. 213, 27–41 (2003). 118. Zachara, N. E., Vosseller, K. & Hart, G. W. Detection and Analysis of Proteins Modified by O-Linked N -Acetylglucosamine. Curr. Protoc. Protein Sci. 12.8.1-12.8.33 (2011). 119. Mcconnell, M. J. & Pachón, J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 29, 1–5 (2011). 120. Bentancor, L. V et al. Evaluation of the Trimeric Autotransporter Ata as a Vaccine Candidate against Acinetobacter baumannii Infections. Infect. Immun. 80, 3381–3388 (2012). 121. Fattahian, Y., Rasooli, I., Latif, S., Gargari, M. & Reza, M. Protection against Acinetobacter baumannii infection via its functional deprivation of bio fi lm associated protein ( Bap ). Microb. Pathog. 51, 402–406 (2011). 122. Bentancor, L. V, Camacho-peiro, A., Bozkurt-guzel, C., Pier, G. B. & Maira-litrán, T. Identification of Ata , a Multifunctional Trimeric Autotransporter of Acinetobacter baumannii. J. Bacteriol. 194, 3950–3960 (2012). 123. Mortensen, B. L. & Skaar, E. P. Microreview Host – microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection. Cell. Microbiol. 14, 1336–1344 (2012). 124. Andersen, K. K., Wang, H. & Otzen, D. E. A Kinetic Analysis of the Folding and Unfolding of OmpA in Urea and Guanidinium Chloride: Single and Parallel Pathways. Biochemistry 51, 8371–83 (2012). 125. Mamat, U. et al. Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins. Microb. Cell Fact. 1–15 (2015). 126. Song, X. et al. Oxidative release of natural glycans for functional glycomics. Nat. Methods 13, 528–534 (2016). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67808 | - |
dc.description.abstract | 細菌的多重抗藥性一直是全球性的公衛問題。根據台灣院內感染監視系統,鮑氏不動桿菌對具碳青黴烯類抗生素有抗藥性的比率,由2002年的3.4%提高到2016的72.6%。因為具碳青黴烯類抗生素是對抗這類革蘭氏陰性細菌的最後一道防線,所以發展新的治療策略來對抗多重抗藥性的鮑氏不動桿菌迫在眉梢。
莢膜多醣是鮑氏不動桿菌的一個致病因子。先前的實驗,用莢膜多醣產生的多株抗體在動物實驗可以提供55%的被動保護力。而且鮑氏不動桿菌被報導具有分歧生合成途徑,即表面的多醣的生合成可以用來修飾一些膜蛋白聚醣基化和用來生合成莢膜多醣。因此帶有莢膜多醣的膜蛋白可能可以作為自然的醣複合疫苗,來有效的活化免疫防禦系統。在本實驗當中,我們利用莢膜多糖產生的抗體作為探針,篩選出外膜蛋白38可能可以做為候選疫苗物,以及其帶有莢膜多醣的位置。結合莢膜多糖特異性抗體和質譜分析法,經抗體純化後的膜蛋白在脫去反應後利用麥可加成法加上二硫蘇糖醇後,從而在外膜蛋白38上發現六個高可能性的醣基化位置(306S, 307T, 90S, 166S, 338S, 334T)。這些發現提供了更廣的視野,來開發針對廣泛抗藥性鮑氏不動桿菌的新一類候選疫苗物。 | zh_TW |
dc.description.abstract | Multidrug resistance in bacteria is always a global health problem. According to the Taiwan Nosocomial Infections Surveillance System, the ratio of carbapenem-resistant Acinetobacter baumannii increased from 3.4% in 2002 to 72.6% in 2016. Since carbapenems are the last line of antibiotics used for the treatment of gram-negative bacteria, developing new therapeutic strategies against multidrug-resistant A. baumannii is urgent.
Capsular polysaccharide (CPS) is a virulence factor of A. baumannii. In our previous study, the CPS-induced antibody provided 55% protection in the animal model. A. baumannii was reported to have a bifurcated pathway for both O-glycosylation in some outer membrane proteins and capsule biosynthesis. Therefore, CPS-anchored outer membrane proteins might serve as natural glycoconjugate vaccines to effectively activate adaptive immunity. In this study, we identified Omp38 as a virulence-relevant vaccine candidate along with its CPS-anchoring position. Together with the CPS-specific antibody and mass-based strategy, the antibody-enriched glycoproteins were subjected to perform a mild -elimination followed by Michael addition of dithiothreitol (BEMAD). These thereby led to the discovery of six highly potential glycosylation sites, 306S, 307T, 90S, 166S, 338S, 334T, on Omp38. As a summary, this study has provided a better insight into the development of the new class of vaccine candidate against extensively drug-resistant (XDR) A. baumannii. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:51:06Z (GMT). No. of bitstreams: 1 ntu-106-R04b46021-1.pdf: 6054268 bytes, checksum: 986cfd3fcc4b8e86660226f35bbf12d8 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 國立臺灣大學碩士學位論文 I
Acknowledgement II 中文摘要 III Abstract IV Contents V List of figures VIII List of tables IX 1. Introduction 1 1.1. Acinetobacter baumannii 1 1.2. Epidemiology and clinical manifestation 2 1.3. Pathogenesis and virulence factors 3 1.4. Antibiotics resistance and treatment options 4 1.5. Glycoconjugate vaccines 5 1.6. Glycosylation 7 1.7. Glycosylation system in Acinetobacter baumannii SK44 8 1.8. Outer membrane protein A family 11 2. Materials and methods 12 2.1. Bacterial strains 12 2.2. Reagents and chemicals 12 2.3. Cell culture and membrane proteins extraction 13 2.4. Expression and purification of phi-ABTF2 endoglycosidase 15 2.5. Polyclonal antibody for A. baumannii SK44lpsB CPS 15 2.6. Immunoprecipitation 15 2.7. BEMAD 16 2.8. In-gel digestion 17 2.9. Tris-HEPES SDS PAGE 18 2.10. Western blot 18 2.11. Alcian Blue staining 18 2.12. DNS assay for detection of endoglycosidase activity 18 2.13. CPS hydrolysis by phi-ABTF2 endoglycosidase 19 2.14. LC-ESI-MS/MS 19 2.15. Sequences alignment and protein modeling 19 3. Results 20 3.1. Membrane protein-specific glycosylation in A. baumannii SK44 20 3.2. Analysis of membrane proteins of A. baumannii SK44 22 3.3. Comparison of Similarity between A. baumannii ATCC 17978 and SK44 by SK44 CPS-specific antibody 24 3.4. Cleavage of SK44 CPS and glycoproteins by phage enzyme ABTF2 27 3.5. Enrich of the glycoprotein by immunoprecipitation 29 3.6. Validate Omp38 is glycoprotein 33 3.7. Detection and Analysis of protein glycosylation 37 3.8. Modeling of glycosylated Omp38 for vaccine design 47 4. Discussions 51 5. References 53 6. Appendix 68 6.1. Amino acids sequence of phi-ABTF2 68 6.2. Amino acids sequence of OmpA/MotB (A1S_1193) 69 6.3. Amino acids sequence of Omp38 (A1S_2840) 70 | |
dc.language.iso | en | |
dc.title | 用於治療廣泛抗藥性鮑氏不動桿菌的候選疫苗 | zh_TW |
dc.title | A vaccine candidate for the treatment of extensively drug-resistant (XDR) Acinetobacter baumannii | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 梁博煌,林曉青,花國鋒 | |
dc.subject.keyword | 鮑氏不動桿菌,莢膜多醣,疫苗,外膜蛋白38,廣泛抗藥性, | zh_TW |
dc.subject.keyword | Acinetobacter baumannii,capsular polysaccharide,vaccine,Omp38,extensively drug-resistance, | en |
dc.relation.page | 70 | |
dc.identifier.doi | 10.6342/NTU201701926 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-07-25 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 5.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。